Avrobio Inc (NAS:AVRO)

$ 16.8 -0.02 (-1.41%) Market Cap: 62.85 Mil Enterprise Value: -27.41 Mil PE Ratio: 2.03 PB Ratio: 0.71 GF Score: 43/100

Ultragenyx Pharmaceutical Inc at Cowen Health Care Conference- Orphan CNS Panel Discussion Transcript
Mar 07, 2023
AVROBIO Inc Virtual Gaucher Disease Program Update Transcript
Dec 07, 2022
AVROBIO Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
AVROBIO Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
AVROBIO Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2022
Ultragenyx Pharmaceutical Inc, Alector Inc, Passage Bio Inc, AVROBIO Inc and Annexon Inc in the Orphan CNS Panel at Cowen Health Care Conference (Virtual) Transcript
Mar 08, 2022
AVROBIO Inc Cystinosis Update Call Transcript
Feb 09, 2022
AVROBIO Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Nov 15, 2021
AVROBIO Inc at Jefferies Gene Therapy/Editing Summit (Virtual) Transcript
Oct 28, 2021
AVROBIO Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021
AVROBIO Inc at JMP Securities Life Sciences Virtual Conference Transcript
Jun 17, 2021
AVROBIO Inc at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 09, 2021
AVROBIO Inc Presents new Clinical Data from Fabry Disease, Cystinosis and Gaucher disease Type 1 Programs Transcript
Feb 08, 2021
AVROBIO Inc at ICR Virtual Conference Transcript
Jan 14, 2021
AVROBIO Inc Virtual R&D Day Transcript
Nov 17, 2020
AVROBIO Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript
Oct 13, 2020
AVROBIO Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2020
Avrobio Inc at WORLDSymposium 2020 Transcript
Feb 11, 2020
AVROBIO Inc Announces Positive Data from Clinical Trials of AVR-RD-01- Call Transcript
Jul 15, 2019

AVROBIO Inc Cystinosis Update Call Transcript

Feb 09, 2022 / 01:00PM GMT

Release Date Price: $19.8 (-6.25%)

Transcript

Operator

Welcome to the AVROBIO WORLDSymposium 2022 Cystinosis Update Call. My name is John, I'll be your operator for today's call. (Operator Instructions) Please note the conference is being recorded.

And I will now turn the call over to Geoff MacKay, Chief Executive Officer of AVROBIO. You may begin.

Geoff MacKay

AVROBIO, Inc. - Co- Founder, President, CEO & Director

Thank you for tuning into our AVROBIO investor update on our investigational gene therapy program in cystinosis. We'll review new data being presented later today by our collaborator, Professor Stephanie Cherqui and her team at UCSD at this week's world symposium in San Diego. The press release announcing these updates can be found on the investor relations section of our website.

Before we begin, I'll review our safe harbor statement. Today's discussion contains statements that are forward looking under the Private Securities Litigation Reform Act of 1995, including statements based on our current plans, expectations and beliefs. Such statements are subject to a number of risks

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.